Capricor Therapeutics: Deadline for Investors to Lead Securities Fraud Lawsuit
Investors who incurred losses exceeding $100,000 in Capricor Therapeutics securities have an opportunity to lead a securities fraud lawsuit. The deadline to act is September 28.
Investors who sustained losses of more than $100,000 in Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities during a specific period may have the opportunity to serve as lead plaintiff in a legal action. Rosen Law Firm is reminding investors of a critical deadline of September 28, 2026.
The lawsuit pertains to purchases of securities made between December 17, 2025, and July 26, 2026. The allegations center on claims of securities fraud, which have allegedly resulted in significant financial losses for investors.
To qualify for a lead plaintiff role, an investor must have experienced losses exceeding $100,000. Rosen Law Firm, which focuses on investor rights, is seeking individuals who meet this criterion to come forward for further information and participation.
Capricor Therapeutics is a biotechnology company developing therapies for conditions such as muscular dystrophy and heart disease. The stock's performance during the class period is under scrutiny in relation to the fraud allegations.